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Views presented are those of the speaker & not 
necessarily official FDA policy 
Process Analytical Technology 
(PAT) 
2 
PAT Guidance 
• Released September 29, 2004 
• Scientific principles and tools 
– Process Understanding   
– PAT Tools 
– Risk-Based Approach 
– Integrated Approach 
 
• Regulatory Strategy accommodating 
innovation  
– Training 
– Lab research 
• www.fda.gov/cder/gmp 
 
• Can this be applied to biotech? 
The Essence of PAT 
Product quality is monitored and controlled during the 
manufacturing process. 
Process decisions are based on assessments of 
material attributes. 
– Forward-feed of incoming material 
• Critical product attributes measured/assessed either 
– Instantaneously (on-line, in-line, at-line) or 
– Before decision point (near at-line) 
Major Stages in Bioprocessing 
Each stage has one 
or more unit 
operations (e.g. 
bioreactors, 
columns, etc.) 
 
In biotech, PAT can 
be applied on a 
unit operation 
basis 
Biotech Unit Operations are 
composed of sequential steps 
Cell culture 
• Bioreactor prep 
• Media fill 
• Inoculate  
• Feed 
• Harvest 
 
CHROMATOGRAPHY 
• Equilibrate the column 
• Load the column 
• Wash away unbound 
material 
• Elute the bound 
material 
Transition from one step to the next 
Decision points 
– Points in a process at which transition decisions are made. 
Decision criteria 
– The information that triggers a transition. 
• Note: In PAT  
– Decision point and criteria must be close enough in timing 
for process control.   
– Criteria related to product attribute 
Decision Criteria Example: eluting 
a protein from a column 
PRODUCT 
CONTAMINANT 
Desirable  
protein 
Impurity 
Decision Criteria – 40 LITER CUT: 
Yield loss 
40 LITERS 
Decision Criteria – 2 Col. Vol. Cut: 
Impurities 
2 COLUMN VOLUMES 
Decision Criteria – A280 Target Cut: 
Better, but still yield loss 
A280 VALUE 
Decision Criteria – A280 Slope Cut: 
Better, but still has impurities 
A280 SLOPE 
Decision Criteria – Component Cut: 
Best balance if impurity can be monitored in-line (or 
near-at-line) to allow active control 
TRACING 
COMPONENTS 
 
Aggregates in theory can 
be measured/detected via 
in-line capable methods 
like CD, light scattering, 
FTIR, A410, other 
techniques  
 
(Brorson and Phillips, BioProcess 
Intl Nov. 2005) 
The biotech world presents a 
unique set of challenges: 
• Production by finicky and highly complex cell-based biological systems  
– highly sensitive to external conditions;  
• In-process intermediates can be complex mixtures  
– desired protein may be a fraction of the bulk liquid;  
• Worrisome, low level impurities (e.g., viruses) still a concern  
– even when present at levels undetectable by even the most sensitive in-
line/on-line/at-line technologies.   
– Removal validation for now 
 
• In contrast, some significant challenges for small molecule drugs may 
not apply to biotech;  
– blending of aqueous protein solutions 
New approaches enabling PAT 
• Systems Biology 
– Metabolomics, proteomics, etc. may identify 
relationships between measurable process variables 
and cell culture state 
• Multivariate data analysis (MVDA) 
– Biotech processes generate huge datasets amenable to 
MVDA to predict process outcomes 
New approaches enabling PAT- 2 
• Robotics and automation 
– Will enable efficient and consistent sampling of 
complex process fluids 
• Advances in Mass spectroscopy 
– Rapid comprehensive biochemical analysis 
• Capacitance probes to measure culture mass 
– On-line measurement of cell biomass and viability 
 
Continuous Processing 
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Continuous mode processing in Biotech 
• Most unit operations are batch mode 
– Discrete input  unit op  discrete output 
• Examples: 
– Batch or fed-batch mode bioreactor 
– Most B&E and flow through columns 
• Continuous mode processing steps do exist 
– Usually one unit within a train of batch mode 
Continuous-mode Bioreactor 
• Media is perfused in and out  
– Rate determined by culture activity 
• Excess cells collected by spin basket 
or other means 
• Used in licensed biotech products for 
seed-train expansion and production 
phase 
Opportunity for continuous processing: 
Simulated Bed Chromatography 
• Two or more columns, connected to one 
another in series 
• Mobile-phase pump, via a six-port, two-
position valve.  
• Switching of the valve will "leapfrog" the 
columns over one another.  
– Effluent can be collected (product) or sent on 
to next column (if feedstock partially depleted 
on product) 
• Used extensively in chemical and food 
industry 
– In theory can be applied to bioprocessing 
but not implemented on wide scale 
Image from 
www.worldofchemicals.com 
Regulatory issues… 
• Continuous chromatography (SMB) 
– Is the separation power equivalent (i.e. higher impurities in 
eluate, yield loss) 
– How do you validate viral clearance? 
• In-line spiking & grab samples? 
– How do you design a representative scale down model? 
• Continuous bioreactors mode 
– Longer time for genetic or production drift of culture  
– More time and portals for system breach- bacterial 
contamination 
– Viral safety- longer period for introduction & growth of 
virus 
CDER’s Emerging 
Technology Team 
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What is the Emerging Technology Team 
(ETT)? 
• A small cross functional team with representation from 
all relevant CDER review and inspection programs 
• Vision: Encourage and support the adoption of 
innovative technology to modernize pharmaceutical 
development and manufacturing where the Agency has 
limited review or inspection experience. Includes: 
− Innovative or novel product, manufacturing process, 
or analytical technology subject to CMC review 
− Existing or planned submission(s) 
23 
The ETT Charter 
• Provides a forum for knowledge sharing and scientific 
discussion 
• Provides consistency, continuity and predictability 
– Facilitates establishment of review and inspection 
standards and policy  
• Supports GMP manufacture of quality product over 
the lifecycle 
• Long term goals: 
– Engage international regulatory agencies to share 
learnings and approaches  
– Modernizing pharmaceutical development and 
manufacturing  
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Role of ETT 
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• Provides perspective on quality review and inspections 
– ETT members serve to lead/co-lead cross-functional team 
during review process 
– Participates or supports relevant inspection(s) and/or pre-
operational visits 
– Identify and capture decisions that may inform future FDA 
approaches and decisions 
• Serve as advocates for innovative technology while balancing 
risk vs. benefit 
• Identify and evaluate roadblocks relating to existing guidance, 
policy, or practice 
• Early applicant engagement with the ETT is recommended 
• Contact us: CDER-ETT@fda.hhs.gov 
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Thank You 
 
Are there questions? 
